Serum Manganese Superoxide Dismutase (MnSOD) and Histological Virulence of Ovarian Cancer

Nishida, Takashi; Sugiyama, Toru; Kataoka, Akio; Tashiro, Masamichi; Yakushiji, M; Ishikawa, Mutsuo

doi:10.1111/j.1447-0756.1993.tb00403.x

Cited by 7 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). Although numerous groups have reported the overexpression of MnSOD protein in tissues of a variety of cancer types 59, 60, 63–65, only few studies investigated the possible clinical significance of serum MnSOD level in cancer management 66–68. We showed here for the first time that the serum MnSOD levels were significantly elevated in NPC patients as compared with healthy controls and that this potential marker alone showed a relatively good power to discriminate NPC patients from controls (AUC value: 0.74) (Fig.…”

Section: Discussionmentioning

confidence: 61%

Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis

Chang

Chen

et al. 2010

Proteomics

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is usually diagnosed at advanced clinical stages, resulting in poor outcomes. To discover serum biomarkers for improved NPC diagnosis and/or management, we simultaneously analyzed the NPC cell secretome and tissue transcriptome to identify candidate genes/proteins that are highly upregulated in NPC tissues and also secreted/released from NPC cells. Among the 30 candidates identified, 11 proteins were chosen for further validation using the serum samples from NPC patients and healthy controls, including cystatin A, cathepsin B, manganese superoxide dismutase and matrix metalloproteinase 2. The results showed that serum levels of all the four proteins were indeed higher in NPC patients versus healthy controls and that the use of a three-marker panel (cystatin A, manganese superoxide dismutase and matrix metalloproteinase 2) can contribute to a better NPC detection than each marker alone. In addition, a higher pretreated serum level of cystatin A was found to be associated with a higher nodal stage and poorer prognosis of NPC patients and cystatin A could modulate the migration and invasion of NPC cells in vitro. Altogether, our results indicate that analysis of both the cancer cell secretome and tissue transcriptome is a feasible strategy for efficient identification of novel NPC serum marker panel.

show abstract

Section: Discussionmentioning

confidence: 61%

Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis

Chang

Chen

et al. 2010

Proteomics

View full text Add to dashboard Cite

show abstract

“…Oberley and Buettner (1979) showed that MnSOD was significantly lowered if not absent in cancer cells, and that MnSOD acts as a tumor suppressor, protecting cells from tumorigenesis in the presence of superoxide (Oberley & Buettner, 1979). Nishida et al (1993), however, showed elevated levels of MnSOD in tumors of ovarian cancer patients. One explanation given for this is that MnSOD is downregulated when tumors are developing but becomes upregulated after the tumor is established (Dhar & St Clair, 2012).…”

Section: Discussionmentioning

confidence: 88%

Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma

Bayer

Spitz

Christensen

et al. 2015

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Increased levels of reactive oxygen species (ROS) such as superoxide anions and hydrogen peroxide have been reported in many cancer cells and they have been implicated in carcinogenesis and tumor progression. Antioxidant enzymes, such as Manganese Superoxide Dismutase (MnSOD or SOD2) and Glutathione Peroxidase-1 (GPx1), act coordinately to neutralize ROS. These enzymes are also thought to contribute to cancer cell resistance to conventional radio-chemotherapies. Although some relationships have been reported between psychosocial factors and the regulation of antioxidant enzymes, little is known about these relationships in the context of cancer progression. The current study investigated the levels of MnSOD and GPx1 in confirmed serous, high-grade tumor tissue from 60 ovarian cancer patients, and explored the relationship between the activity of these enzymes, the levels of tumor norepinephrine (NE), and patient mood as determined via pre-operative questionnaires. MnSOD activity was positively related to depressed mood (p = 0.025) and tumor NE (p = 0.023). In contrast, GPx1 activity was inversely related to fatigue (p = 0.015) and tumor NE (p = 0.009), and was positively associated with vigor (p = 0.024). These findings suggest that psychological state and adrenergic signaling are linked with antioxidant enzyme activity in ovarian cancer and may have implications for patient treatments and outcomes.

show abstract

“…The mitochondrial MnSOD, named also SOD2, is considered as the chief ROS scavenging enzyme in the cell [97]. MnSOD is reduced in many types of cancers, including breast [100][101][102], pancreatic [103] and ovarian cancers [104,105], but it may act as either a tumor suppressor or a tumor promoter depending on cancer type. On the one hand, improved metastasis by MnSOD is a result of stimulation of its expression through H 2 O 2 -dependent mechanisms [106].…”

Section: Mitochondrial Antistress Protective Systemsmentioning

confidence: 99%

Regulation of Mitochondrial Dynamics in Parkinson’s Disease—Is 2-Methoxyestradiol a Missing Piece?

et al. 2021

View full text Add to dashboard Cite

Mitochondria, as “power house of the cell”, are crucial players in cell pathophysiology. Beyond adenosine triphosphate (ATP) production, they take part in a generation of reactive oxygen species (ROS), regulation of cell signaling and cell death. Dysregulation of mitochondrial dynamics may lead to cancers and neurodegeneration; however, the fusion/fission cycle allows mitochondria to adapt to metabolic needs of the cell. There are multiple data suggesting that disturbed mitochondrial homeostasis can lead to Parkinson’s disease (PD) development. 2-methoxyestradiol (2-ME), metabolite of 17β-estradiol (E2) and potential anticancer agent, was demonstrated to inhibit cell growth of hippocampal HT22 cells by means of nitric oxide synthase (NOS) production and oxidative stress at both pharmacologically and also physiologically relevant concentrations. Moreover, 2-ME was suggested to inhibit mitochondrial biogenesis and to be a dynamic regulator. This review is a comprehensive discussion, from both scientific and clinical point of view, about the influence of 2-ME on mitochondria and its plausible role as a modulator of neuron survival.

show abstract

Serum Manganese Superoxide Dismutase (MnSOD) and Histological Virulence of Ovarian Cancer

Cited by 7 publications

References 2 publications

Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis

Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis

Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma

Regulation of Mitochondrial Dynamics in Parkinson’s Disease—Is 2-Methoxyestradiol a Missing Piece?

Contact Info

Product

Resources

About